牛牛AI助理已提取核心訊息
Jin Medical International Ltd., a foreign private issuer, has been notified by the Nasdaq Listing Qualifications Department of non-compliance issues that could lead to the delisting of the company's securities. On December 18, 2023, the company received a letter from Nasdaq for not providing a detailed compliance plan and failing to meet the 300 Round Lot Holder requirement. Jin Medical International has requested a hearing with the Nasdaq Hearings Panel, which has stayed the delisting pending a final decision. The hearing is scheduled for March 14, 2024, where the company must show its ability to regain and maintain compliance. Further complicating matters, on February 21, 2024, Nasdaq cited the company for not filing its Form 20-F for the period ended September 30, 2023, which will also be reviewed at the hearing. Jin Medical International is currently reviewing its position and considering remedial actions to address these compliance issues.
Jin Medical International Ltd., a foreign private issuer, has been notified by the Nasdaq Listing Qualifications Department of non-compliance issues that could lead to the delisting of the company's securities. On December 18, 2023, the company received a letter from Nasdaq for not providing a detailed compliance plan and failing to meet the 300 Round Lot Holder requirement. Jin Medical International has requested a hearing with the Nasdaq Hearings Panel, which has stayed the delisting pending a final decision. The hearing is scheduled for March 14, 2024, where the company must show its ability to regain and maintain compliance. Further complicating matters, on February 21, 2024, Nasdaq cited the company for not filing its Form 20-F for the period ended September 30, 2023, which will also be reviewed at the hearing. Jin Medical International is currently reviewing its position and considering remedial actions to address these compliance issues.
納斯達克上市資格部門已向外國私人發行人Jin Medical International Ltd. 通報了可能導致該公司證券退市的違規問題。2023年12月18日，該公司收到了納斯達克的來信，信中原因是沒有提供詳細的合規計劃，也沒有滿足300輪持有人的要求。Jin Medical International已要求與納斯達克聽證小組舉行聽證會，該小組在做出最終決定之前暫停了除名。聽證會定於2024年3月14日舉行，屆時公司必須表現出其恢復和維持合規的能力。使事情更加複雜的是，納斯達克於2024年2月21日指出，該公司沒有提交截至2023年9月30日的20-F表格，該表格也將在聽證會上進行審查。Jin Medical International目前正在審查其立場，並考慮採取補救措施來解決這些合規問題。
納斯達克上市資格部門已向外國私人發行人Jin Medical International Ltd. 通報了可能導致該公司證券退市的違規問題。2023年12月18日，該公司收到了納斯達克的來信，信中原因是沒有提供詳細的合規計劃，也沒有滿足300輪持有人的要求。Jin Medical International已要求與納斯達克聽證小組舉行聽證會，該小組在做出最終決定之前暫停了除名。聽證會定於2024年3月14日舉行，屆時公司必須表現出其恢復和維持合規的能力。使事情更加複雜的是，納斯達克於2024年2月21日指出，該公司沒有提交截至2023年9月30日的20-F表格，該表格也將在聽證會上進行審查。Jin Medical International目前正在審查其立場，並考慮採取補救措施來解決這些合規問題。
有用
沒用